about
Multidrug resistance: an emerging crisisFocus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase InhibitorsPost-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virusDecreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT.Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replicationThe evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in MoroccoMolecular dynamics simulation in virus research.Probing Mercaptobenzamides as HIV Inactivators via Nucleocapsid Protein 7.HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey.The Genetic Diversity and Evolution of HIV-1 Subtype B Epidemic in Puerto RicoThe emergence of drug resistant HIV variants and novel anti-retroviral therapy.Identification of dual-tropic HIV-1 using evolved neural networks.Biomedical Mutation Analysis (BMA): A software tool for analyzing mutations associated with antiviral resistanceArylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agentsAntiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014.Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling.Microbiology. Exploiting malaria drug resistance to our advantage.Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.Molecular Epidemiology of HIV-1 virus in Puerto Rico: Novel Cases of HIV-1 Subtype C, D and CRF-24BG.Combination ART-Induced Oxidative/Nitrosative Stress, Neurogenic Inflammation and Cardiac Dysfunction in HIV-1 Transgenic (Tg) Rats: Protection by Mg
P2860
Q21284693-1EC7353B-A932-4F91-A9C7-F9EB2E84FF9EQ26764925-99E1E3DD-8776-4CFB-A4BA-25D6FF3EB6A2Q26797870-CA93AFBF-BF42-4547-BCC4-66598AA25369Q33745946-A8165F30-4115-43BE-897C-6BFFE2D5CBB7Q34668776-4F6BCD2C-EC3E-4683-93FC-AFD0E9775348Q35023687-96DCCA3C-59F8-46F1-A272-3471668DBBCDQ36102579-9EFE969C-AD56-4FB4-8B9E-96F17306D01DQ36104304-82B18C19-8EF7-4620-A9C3-776D406B4477Q36342362-7603E3F2-E806-4EB2-A942-537268332E81Q36406860-73C5007D-57E8-42A9-A7FD-A6F3B4D46FE9Q36513021-64CACA7E-8A9C-43AA-9E1A-7440C299036BQ36963496-998FA194-3C40-472C-9C36-4F20F49936ECQ37038403-30F55E63-191F-4921-99A1-38E3F42768D1Q37174078-1D6F2B39-77D5-4232-83BE-77E4781B1248Q38164839-7E6F883F-F1B4-4A7F-A79D-DA7588230B85Q39064765-1A5BF5EA-7538-4382-A057-C208BF0439C9Q39310603-BA6762ED-56F2-43EC-A8D7-2F605DBA3F89Q39638378-F69D5F74-64AA-4D6F-AB7F-009C3B281C93Q42620819-FAB8AE2F-EEF0-40F8-A64E-4DA3EBD7CC50Q42919375-D5EBDFC5-B05B-47DC-AAD3-5509B3467BA0Q47987540-B3F069F5-9E60-4296-8621-3A07BC2AE0D4Q50124348-A5839C73-1E61-457E-9554-857C7FC31CF1Q52586895-47BAA805-0F7A-4665-A252-8F8853D5E6E5Q58776477-04B12F7F-931E-4234-8664-71EDC81048E2
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Clinical management of HIV drug resistance.
@ast
Clinical management of HIV drug resistance.
@en
type
label
Clinical management of HIV drug resistance.
@ast
Clinical management of HIV drug resistance.
@en
prefLabel
Clinical management of HIV drug resistance.
@ast
Clinical management of HIV drug resistance.
@en
P2860
P921
P356
P1433
P1476
Clinical management of HIV drug resistance.
@en
P2093
Frank Maldarelli
Karoll J Cortez
P2860
P304
P356
10.3390/V3040347
P5008
P577
2011-04-01T00:00:00Z
2011-04-14T00:00:00Z